Q2FY19 Result Update Century Plyboards Ltd.

Laminates and MDF pain intensifies; Plywood strong

Century Ply has reported a weak quarter after 2 strong quarters. Sales at INR 565 cr grew 19% YoY and were in line with our estimates driven by strong growth in plywood and contribution from the MDF segment. EBITDA at INR 75 cr was flat YoY but below our and street estimates of INR 90 Cr. EBITDA margins fell from 15.7% in Q2FY18 to 13.3% in Q2FY19. The negative margin surprise was due to higher than expected pain in the laminates and MDF segments. Reported PAT of INR 38 Cr degrew 5% on YoY basis and was below estimates due to the miss in margins and forex losses. We have cut our EPS estimates by ~15% for FY19E and FY20E to factor in the pain in laminates and MDF. Given the volatile earnings enviornment in laminates and MDF, we also cut our target multiple by 10% from 25x P/E FY20E to 22.5x FY20 P/E. However due to strong topline and bottomline growth over FY18-20E and strong RoCE of 25%, we maintain BUY with a revised TP of 287.

Improving margins in plywood; other segments stable

Plywood reported good volume growth of 13%, and margins at 15.5% were much higher than Q2FY18 margins of 14%. Our last quarterly report mentioned of how this improvement in plywood margins is sustainable and now 3 consecutive quarters have witnessed strong plywood margins (16-17% reported margins, which are in line with historical margin trend). Volume growth in plywood is likely to remain strong due to shift from unorganised to organised in the mid premium segment. Other segments such as particle board, CFS, etc. reported stable revenues and margins.

Laminates and MDF margins remain key monitorable

The key underperforming segments are laminates and MDF for 2 quarters in a row. Laminates reported flat revenues on account of a high base whilst margins were lower than muted expectations plagued by rising input prices (paper, phenol). MDF is also facing a severe demand mismatch which led to reduced capacity utilization of 55% (vs 60% plus utilization in Q1FY19). MDF margins crashed to 6% (13% in Q1FY19) on account of lower realization and utilization. Going forward, improvement in margins in laminates and MDF will be key. We feel that the reported margins in these 2 segments, which are 600-800 bps lower than the earlier trajectory, are unsustainable and we do expect an improvement.

Outlook and valuations: 'BUY'

Century is a leader across various wood panel segments and is expected to outpace industry growth. GST at 18% and government's thrust on affordable housing are potent tailwinds for this segment. Inspite of superior return ratios compared to other building material peers and high free cash flow generation, Century is trading at attractive valuations than most peers. We value it at 22.5x FY20E P/E and thus arrive at a revised target price of INR 287.

| Year to March | Q2FY19 | Q2FY18 | % change | Q1FY19 | % change | FY18 | FY19E | FY20E |
|--------------------|--------|--------|----------|--------|----------|-------|-------|-------|
| Net sales (INR cr) | 565 | 475 | 19% | 537 | 5% | 2,025 | 2,263 | 2,553 |
| Growth (%) | | | | | | 11.3 | 11.8 | 12.8 |
| EBITDA (INR cr) | 75 | 75 | 0% | 86 | -13% | 331 | 351 | 433 |
| Adj PAT (INR cr) | 38 | 40 | -5% | 45 | -16% | 168 | 198 | 284 |
| Growth (%) | | | | | | -13 | 18 | 44 |
| Dil. EPS (INR) | | | | | | 8 | 9 | 13 |
| Diluted P/E (x) | | | | | | 23 | 20 | 14 |
| EV/EBITDA (x) | | | | | | 13 | 12 | 9 |
| ROAE (%) | | | | | | 21 | 21 | 24 |

Kshitij Kaji

Research Analyst kshitij.kaji@edelweissfin.com

CMP INR: 180 Rating: BUY

Target Price INR: 287

Upside: 58%

| Bloomberg: | CPBI:IN |
|-------------------------------------|---------|
| 52-week range (INR): | 363/157 |
| Share in issue (cr): | 22 |
| M cap (INR cr): | 4,000 |
| Avg. Daily Vol. BSE/NSE :('000): | 200 |
| Promoter Holding (%) | 72 |

Date: 9th November 2018

Q2FY19 Result Highlights

| Particulars | Q2FY19 | Q2FY18 | % change | Q1FY19 | % change | H1FY19 | H1FY18 | % change |
|-------------------------------|--------|--------|----------|--------|----------|--------|--------|----------|
| Income from operations | 565 | 475 | 19% | 537 | 5% | 1,102 | 914 | 21% |
| Cost of goods sold | 295 | 254 | 16% | 275 | 7% | 570 | 488 | 17% |
| Employee expenses | 84 | 68 | 24% | 79 | 6% | 163 | 136 | 19% |
| Other expenses | 111 | 78 | 42% | 96 | 15% | 207 | 153 | 35% |
| Total operating expenses | 490 | 401 | 22% | 451 | 9% | 941 | 778 | 21% |
| EBITDA | 75 | 75 | 0% | 86 | -13% | 161 | 136 | 19% |
| Depreciation and amortization | 11 | 14 | -20% | 11 | 2% | 22 | 27 | -19% |
| EBIT | 64 | 61 | 5% | 76 | -15% | 140 | 109 | 28% |
| Interest expenses | 16 | 8 | 102% | 13 | 19% | 29 | 14 | 107% |
| Other income | 1 | 0 | NA | 1 | 67% | 2 | 1 | 191% |
| PBT | 49 | 53 | -7% | 63 | -22% | 112 | 95 | 17% |
| Provision for tax | 11 | 13 | -14% | 18 | -37% | 29 | 21 | 37% |
| Core profit | 38 | 40 | -5% | 45 | -16% | 83 | 74 | 12% |
| Extraordinary items | 0 | 0 | NA | 0 | NA | 0 | 0 | NA |
| Adjusted net profit | 38 | 40 | -5% | 45 | -16% | 83 | 74 | 12% |

Financials

| Income statement Year to March | FY16 | FY17 | FY18 | FY19E | (INR crs) FY20E |
|--|----------------------|---------------------|------------------|--------------|--------------------|
| Income from operations | 1,641 | 1,819 | 2,025 | 2,263 | 2,553 |
| Direct costs | 854 | 938 | 986 | 1,154 | 1,302 |
| Employee costs | 236 | 273 | 313 | 344 | 383 |
| | 262 | 296 | 395 | 414 | 435 |
| Other expenses | | | | | |
| Total operating expenses | 1,351 | 1,507 | 1,694 | 1,912 | 2,120 |
| EBITDA | 289 | 312 | 331 | 351 | 433 |
| Depreciation and amortisation | 47 | 59 | 91 | 47 | 50 |
| EBIT | 242 | 253 | 241 | 304 | 383 |
| Interest expenses | 48 | 30 | 35 | 51 | 30 |
| Other income | 6 | 23 | 8 | 14 | 19 |
| Profit before tax | 200 | 245 | 214 | 267 | 371 |
| Provision for tax | 30 | 52 | 46 | 69 | 87 |
| Core profit | 170 | 193 | 168 | 198 | 284 |
| Extraordinary items | 0 | -0 | 0 | 0 | 0 |
| Profit after tax | 170 | 193 | 168 | 198 | 284 |
| Minority Interest | -1 | -3 | -3 | -3 | -3 |
| Share from associates | 0 169 | 100 | 0 165 | 0 195 | 0 281 |
| Adjusted net profit Equity shares outstanding (mn) | 22 | 190 22 | 22 | 22 | 281 |
| EPS (INR) basic | 8 | 9 | 8 | 9 | 13 |
| Diluted shares (Cr) | 22 | 22 | 22 | 22 | 22 |
| | 7.6 | | 7.5 | 8.9 | 12.8 |
| EPS (INR) fully diluted | | 8.6 | | | |
| Dividend per share | 2 | 0 | 1 | 1 | 1 |
| Dividend payout (%) | 30 | 0 | 12 | 12 | 12 |
| Common size metrics- as % of net revenues | EV4.C | EV4.7 | EV4.0 | EVADE | FV20F |
| Year to March | FY16 | FY17 | FY18 | FY19E | FY20E |
| Operating expenses | 82.4 | 82.8 | 83.6 | 84.5 | 83.1 |
| Depreciation | 2.9 | 3.3 | 4.5 | 2.1 | 2.0 |
| Interest expenditure | 2.9 | 1.7 | 1.7 | 2.2 | 1.2 |
| EBITDA margins | 17.6 | 17.2 | 16.4 | 15.5 | 17.0 |
| Net profit margins | 10.3 | 10.5 | 8.1 | 8.6 | 11.0 |
| Growth metrics (%) | | | | | |
| Year to March | FY16 | FY17 | FY18 | FY19E | FY20E |
| Revenues | 3.3 | 10.8 | 11.3 | 11.8 | 12.8 |
| Revenues | | | | 5 0 | 22.2 |
| EBITDA | 13.1 | 7.8 | 6.2 | 5.9 | 23.3 |
| EBITDA | | | | | |
| | 13.1 11.5 13.2 | 7.8 22.4 14.0 | (12.7) (13.2) | 24.8 17.7 | 39.0 43.7 |

Financials

| Balance sheet | | | | | (INR cr) |
|-----------------------------|-------|-------|-------|-------|----------|
| As on 31st March | FY16 | FY17 | FY18 | FY19E | FY20E |
| Equity share capital | 22 | 22 | 22 | 22 | 22 |
| Preference Share Capital | 0 | 0 | 0 | 0 | 0 |
| Reserves & surplus | 507 | 693 | 841 | 1,016 | 1,267 |
| Shareholders funds | 529 | 715 | 863 | 1,038 | 1,289 |
| Secured loans | 470 | 521 | 436 | 386 | 286 |
| Unsecured loans | 5 | 97 | 97 | 97 | 97 |
| Borrowings | 474 | 619 | 534 | 484 | 384 |
| Minority interest | 9 | 12 | 18 | 18 | 18 |
| Sources of funds | 1,012 | 1,345 | 1,415 | 1,540 | 1,691 |
| Gross block | 298 | 412 | 858 | 888 | 928 |
| Depreciation | 48 | 106 | 197 | 244 | 294 |
| Net block | 250 | 306 | 661 | 645 | 635 |
| Capital work in progress | 102 | 299 | 126 | 0 | 0 |
| Total fixed assets | 352 | 605 | 787 | 645 | 635 |
| Unrealised profit | 0 | 0 | 0 | 0 | 0 |
| Investments | 6 | 6 | 35 | 35 | 35 |
| Inventories | 298 | 301 | 383 | 403 | 441 |
| Sundry debtors | 284 | 342 | 355 | 391 | 434 |
| Cash and equivalents | 39 | 67 | 18 | 257 | 391 |
| Loans and advances | 90 | 160 | 80 | 80 | 80 |
| Other current assets | 0 | 0 | 0 | 0 | 0 |
| Total current assets | 711 | 870 | 835 | 1,130 | 1,345 |
| Sundry creditors and others | 153 | 219 | 272 | 298 | 350 |
| Provisions | 9 | 19 | 30 | 32 | 33 |
| Total CL & provisions | 162 | 238 | 302 | 329 | 383 |
| Net current assets | 549 | 633 | 534 | 801 | 962 |
| Net Deferred tax | 65 | 67 | 59 | 59 | 59 |
| Misc expenditure | 39 | 34 | 0 | 0 | 0 |
| Uses of funds | 1,012 | 1,345 | 1,415 | 1,540 | 1,691 |
| Book value per share (INR) | 24 | 32 | 39 | 47 | 58 |

Cash flow statement (INR crs)

| Year to March | FY16 | FY17 | FY18 | FY19E | FY20E |
|---|------|------|------|-------|-------|
| Net profit | 170 | 194 | 168 | 198 | 284 |
| Add: Depreciation | 47 | 59 | 91 | 47 | 50 |
| Add: Misc expenses written off/Other Assets | 23 | 5 | 34 | 0 | 0 |
| Add: Deferred tax | -59 | -2 | 8 | 0 | 0 |
| Add: Others | -1 | -3 | -3 | -3 | -3 |
| Gross cash flow | 180 | 252 | 298 | 241 | 331 |
| Less: Changes in W. C. | -14 | 55 | -50 | 28 | 27 |
| Operating cash flow | 194 | 197 | 348 | 213 | 304 |
| Less: Capex | 121 | 312 | 147 | 30 | 40 |
| Free cash flow | 73 | -115 | 201 | 183 | 264 |

Financials

Ratios

| Year to March | FY16 | FY17 | FY18 | FY19E | FY20E |
|------------------------------|------|------|------|-------|-------|
| ROAE (%) | 37 | 31 | 21 | 21 | 24 |
| ROACE (%) | 26 | 23 | 18 | 21 | 25 |
| Debtors (days) | 63 | 69 | 64 | 63 | 62 |
| Current ratio | 4.4 | 4 | 3 | 3 | 4 |
| Debt/Equity | 0.9 | 0.9 | 0.6 | 0.5 | 0.3 |
| Inventory (days) | 66 | 60 | 69 | 65 | 63 |
| Payable (days) | 34 | 44 | 49 | 48 | 50 |
| Cash conversion cycle (days) | 95 | 85 | 84 | 80 | 75 |
| Debt/EBITDA | 1.6 | 2 | 2 | 1 | 1 |
| Adjusted debt/Equity | 0.8 | 0.8 | 0.6 | 0.2 | (0.0) |


Valuation parameters

| Year to March | FY16 | FY17 | FY18 | FY19E | FY20E |
|--------------------|------|------|--------|-------|-------|
| Diluted EPS (INR) | 7.6 | 8.6 | 7.5 | 8.9 | 12.8 |
| Y-o-Y growth (%) | 13.5 | 12.6 | (11.8) | 17.7 | 43.7 |
| CEPS (INR) | 9.7 | 11.2 | 11.6 | 11.0 | 15.0 |
| Diluted P/E (x) | 23.3 | 20.7 | 23.4 | 19.9 | 13.9 |
| Price/BV(x) | 7.4 | 5.5 | 4.6 | 3.8 | 3.1 |
| EV/Sales (x) | 2.7 | 2.5 | 2.2 | 1.8 | 1.5 |
| EV/EBITDA (x) | 15.1 | 14.4 | 13.4 | 11.9 | 9.1 |
| Diluted shares O/S | 22.3 | 22.3 | 22.3 | 22.3 | 22.3 |
| Basic EPS | 7.6 | 8.6 | 7.5 | 8.9 | 12.8 |
| Basic PE (x) | 23.3 | 20.7 | 23.4 | 19.9 | 13.9 |
| Dividend yield (%) | 1.3 | 0.0 | 0.4 | 0.5 | 0.7 |

Edelweiss Broking Limited, 1st Floor, Tower 3, Wing B, Kohinoor City Mall, Kohinoor City, Kirol Road, Kurla(W) Board: (91-22) 4272 2200

Vinay Khattar Head Research vinay.khattar@edelweissfin.com

| Rating | Expected to |
|--------|---|
| Buy | appreciate more than 15% over a 12-month period |
| Hold | appreciate between 5-15% over a 12-month period |
| Reduce | Return below 5% over a 12-month period |





Disclaimer

Edelweiss Broking Limited ("EBL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its Associates (list available on www.edelweissfin.com) are organized around five broad business groups – Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance.

Broking services offered by Edelweiss Broking Limited under SEBI Registration No.: INZ000005231; Name of the Compliance Officer: Mr. Brijmohan Bohra, Email ID: complianceofficer.ebl@edelweissfin.com Corporate Office: Edelweiss House, Off CST Road, Kalina, Mumbai - 400098; Tel. 18001023335/022-42722200/022-40094279

This Report has been prepared by Edelweiss Broking Limited in the capacity of a Research Analyst having SEBI Registration No.INH000000172 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject EBL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. EBL reserves the right to make modifications and alterations to this statement as may be required from time to time. EBL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. EBL is committed to providing independent and transparent recommendation to its clients. Neither EBL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance. The disclosures o

EBL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the EBL to present the data. In no event shall EBL be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the EBL through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

EBL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. EBL may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with EBL.

EBL or its associates may have received compensation from the subject company in the past 12 months. EBL or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. EBL or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or EBL's associates may have financial interest in the subject company. EBL, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No EBL has financial interest in the subject companies: No

EBL's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

EBL has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at www.nseindia.com

Analyst Certification:

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.



Disclaimer

Additional Disclaimer for U.S. Persons

Edelweiss is not a registered broker – dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition Edelweiss is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by Edelweiss, including the products and services described herein are not available to or intended for U.S. persons.

This report does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. "U.S. Persons" are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed "US Persons" under certain rules.

Transactions in securities discussed in this research report should be effected through Edelweiss Financial Services Inc.

Additional Disclaimer for U.K. Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Order"); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons").

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

Additional Disclaimer for Canadian Persons

Edelweiss is not a registered adviser or dealer under applicable Canadian securities laws nor has it obtained an exemption from the adviser and/or dealer registration requirements under such law. Accordingly, any brokerage and investment services provided by Edelweiss, including the products and services described herein, are not available to or intended for Canadian persons.

This research report and its respective contents do not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services.

Disclosures under the provisions of SEBI (Research Analysts) Regulations 2014 (Regulations)

Edelweiss Broking Limited ("EBL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its associates are organized around five broad business groups — Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance. There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. This research report has been prepared and distributed by Edelweiss Broking Limited ("Edelweiss") in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No.INH000000172.